Recent Updates
Recently added Catalysts
GRAL Positive Sentiment

GRAIL to Announce First Quarter 2026 Financial Results

Key Takeaway: GRAIL, Inc. announced it will release its financial results for the first quarter of 2026 on May 5, 2026. Following the release, a webcast and conference call will be held to discuss the results and business progress. GRAIL focuses on early cancer detection using advanced technologies.
Price reaction · baseline $51.05 (2026-04-21 close) · hit after-hours · clean, no other GRAL news in the window
day 0 close · peak
+3%

Market Sentiment Analysis

POSITIVE FACTORS

  • GRAIL is committed to early cancer detection, enhancing treatment outcomes.
  • The company is actively engaging with investors through a webcast.
  • GRAIL's innovative technology aims to alleviate the global burden of cancer.

Full Press Release Details

MENLO PARK, Calif.,April 22, 2026/PRNewswire/ -- GRAIL, Inc. (Nasdaq:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.
First Quarter 2026 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website atinvestors.grail.com.
To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.
About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.For more information, visitgrail.com.

Frequently Asked Questions

When will GRAIL announce its Q1 2026 financial results?

GRAIL will announce its Q1 2026 financial results on May 5, 2026.

What time is the GRAIL conference call scheduled?

The conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET.

How can I access the GRAIL webcast?

The webcast can be accessed via GRAIL's investor relations website.

What is GRAIL's mission?

GRAIL's mission is to detect cancer early when it can be cured.

Last updated: Apr 22, 2026